[Skip to Content]
[Skip to Content Landing]
Views 1,489
Citations 0
Editorial
December 11, 2018

Vitamin D Receptor Agonists for Patients Undergoing Hemodialysis

Author Affiliations
  • 1Department of Medicine, Duke University School of Medicine, Durham, North Carolina
  • 2Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
JAMA. 2018;320(22):2319-2321. doi:10.1001/jama.2018.17477

Cardiovascular disease (CVD) is the leading cause of death among patients with end-stage kidney disease (ESKD) who are undergoing hemodialysis, yet many standard cardioprotective therapies have not been effective in reducing CVD in this patient population.1 This reality has motivated the quest to identify dialysis-related and kidney disease–specific factors that promote CVD.

×